Objective:To explore the predictive role of dynamic changes in serum Golgi protein 73 (GP73) and its inflammatory influencing factors on the reversal of hepatitis B virus-related liver fibrosis.Methods:Two hundred and seventy-eight patients with hepatitis B virus-related liver fibrosis who received entecavir or combined Fuzheng Huayu tablets treatment and completed two liver biopsies (biopsy) in Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from September 2014 to July 2019 were selected. The correlation between serum GP73 level and fibrosis stage (Ishak) and inflammation grade (HAI) was analyzed. The patients were divided into a fibrosis reversal group (Ishak decreased≥1 point) and a non-reversal group (Ishak score remained unchanged or increased), and an inflammation improvement group (ΔHAI≤-2) and a non-improvement group (ΔHAI>-2) according to the pathological changes of liver tissue before and after treatment. The cross-sectional value of GP73, its change value (ΔGP73), and the role of inflammatory influencing factors on the liver before and after treatment were evaluated for their predictive efficacy regarding liver fibrosis regression. The receiver operating characteristic curve was used to explore the predictive value of serum ΔGP73 combined with liver stiffness change value (ΔLSM) for the reversal of hepatitis B virus-related liver fibrosis. One-way analysis of variance was used to compare the data between the groups of quantitative data, and a paired t-test or rank sum test was used for the data before and after treatment. The χ2 test was used to compare the differences between the groups of enumeration data. Spearman and Pearson correlation methods were used for correlation analysis. Results:The serum GP73 level was higher in the cirrhosis group than that in the group without significant fibrosis ( P<0.01). The GP73 level was higher in patients with moderate and severe inflammation than that in the mild group ( P<0.05). Pre-treatment serum GP73 was positively correlated with fibrosis stage ( r=0.248), inflammation grade ( r=0.318), and alanine aminotransferase level ( r=0.203) ( P<0.01). The area under the receiver operating characteristic curve (AUROC) for the predictive ability of post-treatment GP73 levels in the fibrosis reversal was 0.633 (95% CI: 0.573-0.689, sensitivity 62.68%, and specificity 59.56%). The decrease in ΔGP73 was significantly higher in the liver fibrosis reversal group ( n=142) than that in the non-reversal group ( n=136) [-39.22(-85.08,-14.31) ng/mL vs. -30.06(-61.29,-5.84) ng/mL, P<0.01]. ΔGP73 was also associated with liver inflammation changes (AUROC=0.634, 95% CI: 0.574-0.690, sensitivity of 51.64%, specificity of 69.87%). Additionally, the predictive effectiveness of GP73 for fibrosis reversal improved after normalization of serum ALT (AUROC: 0.651 vs. 0.522 at baseline). ΔGP73 combined with ΔLSM had improved the AUROC predictive effectiveness from single indicators of 0.609 (ΔGP73) and 0.656 (ΔLSM) to 0.800 (95% CI: 0.662-0.899), with specificity increasing from 72.22% to 86.11%. Conclusion:Serum GP73 level is positively correlated with the degree of liver fibrosis and inflammation. Serum GP73 levels and ΔGP73 can predict the reversal of fibrosis, with liver inflammation being an important influencing factor following treatment. ΔGP73 combined with ΔLSM can significantly optimize the evaluation efficiency of liver fibrosis reversal.

Objective:To explore the predictive role of dynamic changes in serum Golgi protein 73 (GP73) and its inflammatory influencing factors on the reversal of hepatitis B virus-related liver fibrosis.Methods:Two hundred and seventy-eight patients with hepatitis B virus-related liver fibrosis who received entecavir or combined Fuzheng Huayu tablets treatment and completed two liver biopsies (biopsy) in Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from September 2014 to July 2019 were selected. The correlation between serum GP73 level and fibrosis stage (Ishak) and inflammation grade (HAI) was analyzed. The patients were divided into a fibrosis reversal group (Ishak decreased≥1 point) and a non-reversal group (Ishak score remained unchanged or increased), and an inflammation improvement group (ΔHAI≤-2) and a non-improvement group (ΔHAI>-2) according to the pathological changes of liver tissue before and after treatment. The cross-sectional value of GP73, its change value (ΔGP73), and the role of inflammatory influencing factors on the liver before and after treatment were evaluated for their predictive efficacy regarding liver fibrosis regression. The receiver operating characteristic curve was used to explore the predictive value of serum ΔGP73 combined with liver stiffness change value (ΔLSM) for the reversal of hepatitis B virus-related liver fibrosis. One-way analysis of variance was used to compare the data between the groups of quantitative data, and a paired t-test or rank sum test was used for the data before and after treatment. The χ2 test was used to compare the differences between the groups of enumeration data. Spearman and Pearson correlation methods were used for correlation analysis. Results:The serum GP73 level was higher in the cirrhosis group than that in the group without significant fibrosis ( P<0.01). The GP73 level was higher in patients with moderate and severe inflammation than that in the mild group ( P<0.05). Pre-treatment serum GP73 was positively correlated with fibrosis stage ( r=0.248), inflammation grade ( r=0.318), and alanine aminotransferase level ( r=0.203) ( P<0.01). The area under the receiver operating characteristic curve (AUROC) for the predictive ability of post-treatment GP73 levels in the fibrosis reversal was 0.633 (95% CI: 0.573-0.689, sensitivity 62.68%, and specificity 59.56%). The decrease in ΔGP73 was significantly higher in the liver fibrosis reversal group ( n=142) than that in the non-reversal group ( n=136) [-39.22(-85.08,-14.31) ng/mL vs. -30.06(-61.29,-5.84) ng/mL, P<0.01]. ΔGP73 was also associated with liver inflammation changes (AUROC=0.634, 95% CI: 0.574-0.690, sensitivity of 51.64%, specificity of 69.87%). Additionally, the predictive effectiveness of GP73 for fibrosis reversal improved after normalization of serum ALT (AUROC: 0.651 vs. 0.522 at baseline). ΔGP73 combined with ΔLSM had improved the AUROC predictive effectiveness from single indicators of 0.609 (ΔGP73) and 0.656 (ΔLSM) to 0.800 (95% CI: 0.662-0.899), with specificity increasing from 72.22% to 86.11%. Conclusion:Serum GP73 level is positively correlated with the degree of liver fibrosis and inflammation. Serum GP73 levels and ΔGP73 can predict the reversal of fibrosis, with liver inflammation being an important influencing factor following treatment. ΔGP73 combined with ΔLSM can significantly optimize the evaluation efficiency of liver fibrosis reversal.

Collagen hydrogel is a new type of wound dressing. The combination of the advantages of collagen and hydrogel can effectively exert their respective advantages in wound repair and regeneration. In recent years, the use of physical and chemical method to improve the mechanical properties and biological functions of collagen hydrogels to make them more suitable for wound environment has become a hotspot in scientific research and clinical trials. This review systematically summarized the theoretical basis, application status and research progress of collagen hydrogel in wound repair, and analyzed the current advantages, limitations, and future research directions, to provide reference and directions for the development of collagen hydrogel and its clinical application in wound repair field.

Collagen hydrogel is a new type of wound dressing. The combination of the advantages of collagen and hydrogel can effectively exert their respective advantages in wound repair and regeneration. In recent years, the use of physical and chemical method to improve the mechanical properties and biological functions of collagen hydrogels to make them more suitable for wound environment has become a hotspot in scientific research and clinical trials. This review systematically summarized the theoretical basis, application status and research progress of collagen hydrogel in wound repair, and analyzed the current advantages, limitations, and future research directions, to provide reference and directions for the development of collagen hydrogel and its clinical application in the field of wound repair.

Collagen hydrogel is a new type of wound dressing. The combination of the advantages of collagen and hydrogel can effectively exert their respective advantages in wound repair and regeneration. In recent years, the use of physical and chemical method to improve the mechanical properties and biological functions of collagen hydrogels to make them more suitable for wound environment has become a hotspot in scientific research and clinical trials. This review systematically summarized the theoretical basis, application status and research progress of collagen hydrogel in wound repair, and analyzed the current advantages, limitations, and future research directions, to provide reference and directions for the development of collagen hydrogel and its clinical application in wound repair field.

Collagen hydrogel is a new type of wound dressing. The combination of the advantages of collagen and hydrogel can effectively exert their respective advantages in wound repair and regeneration. In recent years, the use of physical and chemical method to improve the mechanical properties and biological functions of collagen hydrogels to make them more suitable for wound environment has become a hotspot in scientific research and clinical trials. This review systematically summarized the theoretical basis, application status and research progress of collagen hydrogel in wound repair, and analyzed the current advantages, limitations, and future research directions, to provide reference and directions for the development of collagen hydrogel and its clinical application in the field of wound repair.

Objective: To analyze the association of cytogenetic abnormalities with the prognosis of chronic myeloid leukemia (CML) patients in tyrosine kinase inhibitors (TKI) era. Methods: Karyotype analysis of chromosome G-banding was carried out in 387 newly diagnosed CML patients by short-term culture of bone marrow cells. The correlation of cytogenetic abnormalities and CML progression was explored in combination with ABL tyrosine point mutations. Result: Of 387 patients with positive BCR-ABL fusion gene assayed by fluorescence in situ hybridization (FISH) technique, 94.1% (364/387) patients were Ph positive and 5.9% (23/387) Ph negative; 320 patients (87.9%) had a translocation t (9;22) (q34;q11) and 5 (1.4%) a variant translocation t (v;22) . Additional cytogenetic aberrations (ACA) at diagnosis were found in 10.7% (39/387) Ph⁺ patients, major route ACA in 22 (56.4%) cases and minor route ACA in 15 (38.5%) cases and 2 patients (5.1%) lacked the Y chromosome (−Y) ; 23.4% (71/303) patients occurred ACA during TKI treatment and the most frequent abnormalities were abnormal chromosome numbersd, which were likely associated with high proportion of disease progression (χ²=168.21, P<0.001) and ABL tyrosine point mutations (χ²=29.04, P<0.001) . Newly diagnosed CML-CP patients with t (9;22) (q34;q11) had a longer event-free survival (EFS) and disease-free survival (DFS) rates than that of patients with ACA (P=0.037; P=0.003) , while the overall survival (OS) had no significant differences (P=0.209) . As for CML-CP patients that occurred ACA during TKI therapy would have a marked low OS, EFS and DFS (all P<0.001) compared with no ACA occurred patients. Survival of advanced patients that occurred ACA were dramatically reduced. Conclusion ACA often emerged during the disease progress in CML patients, regular and timely detection of chromosomes karyotype and ABL tyrosine point mutations during TKI treatment was important for therapeutic evaluation, progress and prognosis of CML.

Objective To compare the efficacy and safety of ivermectin with metronidazole in patients with intestinal acariasis.Methods 24 patients with typical intestinal acariasis were selected and divided into two groups,each group had 12 members.Double-blind,randomized clinical trial of ivermectin versus metronidazole was assigned.Results 24 patients completed 3 courses.The total cure rate of ivermectin and metronidazole were 100%(12/12) and 25%(3/12),respectively.There was statistical difference between the two groups(P